Shanghai Fosun Pharmaceutical (SHA:600196) subsidiary Henlius signed a licensing agreement with Dr. Reddy's to develop, produce, and commercialize HLX15 in the US and 42 European countries, including the UK and Switzerland.
HLX15 is a biosimilar of Daratumumab and is intended to treat multiple myeloma, according to a Thursday filing with the Shanghai bourse.
The deal includes an upfront payment of $33 million and potential milestone payments of up to $98.6 million yuan.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。